
## Gerald P Linette

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/549230/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science, 2015, 348, 803-808.	12.6	1,139
2	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 1374-1385.	10.7	1,034
3	Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood, 2013, 122, 863-871.	1.4	932
4	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2016, 17, 1558-1568.	10.7	827
5	A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nature Medicine, 2019, 25, 454-461.	30.7	466
6	pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Medicine, 2016, 8, 11.	8.2	350
7	CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro-Oncology, 2018, 20, 1429-1438.	1.2	197
8	IL-12p70–producing patient DC vaccine elicits Tc1-polarized immunity. Journal of Clinical Investigation, 2013, 123, 3383-3394.	8.2	137
9	CAR T-Cell Therapies in Glioblastoma: A First Look. Clinical Cancer Research, 2018, 24, 535-540.	7.0	103
10	Noninvasive Determination of Melanoma Depth using a Handheld Photoacoustic Probe. Journal of Investigative Dermatology, 2017, 137, 1370-1372.	0.7	54
11	Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nature Communications, 2021, 12, 4365.	12.8	53
12	Neoantigen Vaccines Pass the Immunogenicity Test. Trends in Molecular Medicine, 2017, 23, 869-871.	6.7	45
13	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23662-23670.	7.1	40
14	BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced <i>BRAFV600</i> -mutant Melanoma. Clinical Cancer Research, 2022, 28, 1098-1106.	7.0	32
15	Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma. Melanoma Research, 2018, 28, 44-51.	1.2	31
16	Management Controversies in Head and Neck Melanoma. JAMA Facial Plastic Surgery, 2017, 19, 53-62.	2.1	19
17	Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments. , 2021, 9, e003148.		18
18	Biomarkers in melanoma: Stage III and IV disease. Expert Review of Molecular Diagnostics, 2005, 5, 65-74.	3.1	17

GERALD P LINETTE

#	Article	IF	CITATIONS
19	Dendritic cell-based vaccines. Oncolmmunology, 2013, 2, e26512.	4.6	15
20	<scp>TRPM1</scp> (melastatin) expression is an independent predictor of overall survival in clinical <scp>AJCC</scp> stage I and <scp>II</scp> melanoma patients. Journal of Cutaneous Pathology, 2017, 44, 328-337.	1.3	13
21	Primary Bone Tumors: Challenges and Opportunities for CAR-T Therapies. Journal of Bone and Mineral Research, 2019, 34, 1780-1788.	2.8	12
22	18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy Journal of Clinical Oncology, 2018, 36, 192-192.	1.6	11
23	Amino-Terminal Extended Peptide Single-Chain Trimers Are Potent Synthetic Agonists for Memory Human CD8+ T Cells. Journal of Immunology, 2012, 188, 5839-5849.	0.8	5
24	RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma. Journal of Neuro-Oncology, 2019, 141, 95-102.	2.9	5
25	Preclinical evaluation of cancer immune therapy using patientâ€derived tumor antigenâ€specific T cells in a novel xenograft platform. Clinical and Translational Immunology, 2021, 10, e1246.	3.8	4
26	On the Twentieth Anniversary of Dendritic Cell Vaccines – Riding the Next Wave. Cancer Research, 2022, 82, 966-968.	0.9	4
27	Health-related quality of life in patients with malignant melanoma by stage and treatment status. Journal of the American Academy of Dermatology, 2021, 85, 486-489.	1.2	2
28	Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy Journal of Clinical Oncology, 2017, 35, 80-80.	1.6	2
29	Use of targeted next generation sequencing (NGS) to assess mutational load in glioblastoma (GBM) Journal of Clinical Oncology, 2017, 35, 2027-2027.	1.6	1